Navigating Complex Legal Terrains: Updates on PFAS and Insulin Litigation for Local Leaders
Local governments in England and Wales are increasingly taking legal action on various fronts to address societal concerns and hold larger actors accountable. In recent years, two significant areas of litigation have emerged, involving per- and polyfluoroalkyl substances (PFAS) and the skyrocketing prices of insulin.
PFAS are harmful chemicals that contaminate water, soil, and air in communities, leading to public health concerns and significant impacts on local governments. Litigation in this area has seen progress, with lawsuits targeting manufacturers for their role in water pollution. A recent $10.3 billion settlement offer from 3M aims to address claims from public water systems affected by PFAS contamination, providing financial relief for affected communities.
On the other hand, insulin pricing litigation has also gained traction, with cities filing lawsuits against manufacturers and pharmacy benefit managers for price gouging. These lawsuits allege unfair practices leading to exorbitant insulin prices, impacting cities as employers and patients. Local governments are actively engaging in this litigation to seek immediate relief and address financial burdens caused by inflated insulin prices.
Cities like Miami, Baltimore, and Cleveland have taken legal action against insulin manufacturers and PBMs, alleging price inflation schemes and violations of consumer protection laws. Local governments with self-funded insurance or health benefit plans for employees are eligible plaintiffs in this litigation track.
As these legal cases unfold, local leaders in England and Wales are advised to consult with their legal counsel to determine the relevance and potential engagement in these litigations. The National League of Cities will continue to monitor these cases and provide updates on their legal advocacy efforts. Stay connected with NLC’s federal advocacy newsletter for the latest updates on these legal actions.